PIM2 Antibody - #DF9887
| Product: | PIM2 Antibody |
| Catalog: | DF9887 |
| Description: | Rabbit polyclonal antibody to PIM2 |
| Application: | WB IHC IF/ICC |
| Reactivity: | Human, Mouse, Rat |
| Prediction: | Pig, Bovine, Horse, Sheep, Rabbit, Dog |
| Mol.Wt.: | 34 kDa; 34kD(Calculated). |
| Uniprot: | Q9P1W9 |
| RRID: | AB_2843081 |
Related Downloads
Protocols
Product Info
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Cite Format: Affinity Biosciences Cat# DF9887, RRID:AB_2843081.
Fold/Unfold
OTTHUMP00000025825; Pim 2 oncogene; Pim 2h; Pim-2h; PIM2; PIM2 Oncogene; PIM2_HUMAN; Pim2h; Proto Oncogene PIM2; Proto-oncogene Pim-2 (serine threonine kinase); Serine/threonine kinase PIM2; Serine/threonine-protein kinase Pim-2;
Immunogens
Highly expressed in hematopoietic tissues, in leukemic and lymphoma cell lines, testis, small intestine, colon and colorectal adenocarcinoma cells. Weakly expressed in normal liver, but highly expressed in hepatocellular carcinoma tissues.
- Q9P1W9 PIM2_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MLTKPLQGPPAPPGTPTPPPGGKDREAFEAEYRLGPLLGKGGFGTVFAGHRLTDRLQVAIKVIPRNRVLGWSPLSDSVTCPLEVALLWKVGAGGGHPGVIRLLDWFETQEGFMLVLERPLPAQDLFDYITEKGPLGEGPSRCFFGQVVAAIQHCHSRGVVHRDIKDENILIDLRRGCAKLIDFGSGALLHDEPYTDFDGTRVYSPPEWISRHQYHALPATVWSLGILLYDMVCGDIPFERDQEILEAELHFPAHVSPDCCALIRRCLAPKPSSRPSLEEILLDPWMQTPAEDVPLNPSKGGPAPLAWSLLP
Predictions
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - Q9P1W9 As Substrate
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| T3 | Phosphorylation | Uniprot | |
| T15 | Phosphorylation | Uniprot | |
| Y32 | Phosphorylation | Uniprot | |
| K40 | Ubiquitination | Uniprot | |
| K61 | Ubiquitination | Uniprot | |
| K89 | Ubiquitination | Uniprot | |
| K132 | Ubiquitination | Uniprot | |
| K165 | Ubiquitination | Uniprot | |
| K179 | Ubiquitination | Uniprot | |
| T195 | Phosphorylation | Q9P1W9 (PIM2) | Uniprot |
| S204 | Phosphorylation | Q9P1W9 (PIM2) | Uniprot |
PTMs - Q9P1W9 As Enzyme
| Substrate | Site | Source |
|---|---|---|
| P01106 (MYC) | S329 | Uniprot |
| P14618 (PKM) | T454 | Uniprot |
| P23588 (EIF4B) | S406 | Uniprot |
| P38936 (CDKN1A) | T145 | Uniprot |
| P38936 (CDKN1A) | S146 | Uniprot |
| P41279 (MAP3K8) | S400 | Uniprot |
| P41279 (MAP3K8) | S413 | Uniprot |
| P46527 (CDKN1B) | T157 | Uniprot |
| P46527 (CDKN1B) | T198 | Uniprot |
| P49815 (TSC2) | S1798 | Uniprot |
| Q00987 (MDM2) | S166 | Uniprot |
| Q00987 (MDM2) | S186 | Uniprot |
| Q13541 (EIF4EBP1) | S65 | Uniprot |
| Q92934 (BAD) | S75 | Uniprot |
| Q92934 (BAD) | S99 | Uniprot |
| Q92934 (BAD) | S118 | Uniprot |
| Q9P1W9 (PIM2) | T195 | Uniprot |
| Q9P1W9 (PIM2) | S204 | Uniprot |
Research Backgrounds
Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilization of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade; this process requires phosphorylation of MAP3K8/COT. Promotes growth factor-independent proliferation by phosphorylation of cell cycle factors such as CDKN1A and CDKN1B. Involved in the positive regulation of chondrocyte survival and autophagy in the epiphyseal growth plate.
Autophosphorylated.
Highly expressed in hematopoietic tissues, in leukemic and lymphoma cell lines, testis, small intestine, colon and colorectal adenocarcinoma cells. Weakly expressed in normal liver, but highly expressed in hepatocellular carcinoma tissues.
Interacts with MYC.
Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. PIM subfamily.
Research Fields
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.